Rapid onset honeycombing fibrosis in spontaneously breathing patient with COVID-19.

Eur Respir J

AP-HP, Service de médecine intensive-réanimation, Hôpital de Bicêtre, Le Kremlin-Bicêtre, France.

Published: August 2020

https://bit.ly/2B7fRcA

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7338404PMC
http://dx.doi.org/10.1183/13993003.01808-2020DOI Listing

Publication Analysis

Top Keywords

rapid onset
4
onset honeycombing
4
honeycombing fibrosis
4
fibrosis spontaneously
4
spontaneously breathing
4
breathing patient
4
patient covid-19
4
covid-19 https//bitly/2b7frca
4
rapid
1
honeycombing
1

Similar Publications

The COVID-19 pandemic highlighted the critical need for well-established clinical research networks capable of rapid response during infectious disease outbreaks. In Southeast Asia, the absence of active research networks at the onset of the COVID-19 contributed to gaps in regional preparedness. This manuscript discusses the challenges and opportunities identified during a regional workshop held in Singapore (February 26 to March 1, 2024), which brought together 130 stakeholders from across the region.

View Article and Find Full Text PDF

Management of cardiac trauma and penetrating cardiac injuries with severe hemorrhagic shock: a 5-year experience.

J Trauma Inj

December 2024

Department of Cardiovascular and Thoracic Surgery, Tam Anh Hospital, Ho Chi Minh City, Vietnam.

Purpose: The diagnosis and management of cardiac trauma and penetrating cardiac injuries pose significant challenges in emergency settings due to the rapid onset of life-threatening complications. This paper presents a narrative review to better describe the etiology, presentation, and management of penetrating cardiac trauma, offering insights and experiences related to performing emergency surgery for such cases.

Methods: We compiled cases of traumatic cardiac rupture and penetrating cardiac injuries accompanied by severe hemorrhagic shock that necessitated emergency surgery.

View Article and Find Full Text PDF

First line treatment with subcutaneous efgartigimod in impending myasthenic crisis: a case report.

Ther Adv Neurol Disord

December 2024

Department of Neurology, Faculty of Medicine, University of Augsburg, Stenglinstrasse 2, Augsburg 86156, Germany.

In acetylcholine receptor (AChR) antibody-positive generalized myasthenia gravis (gMG), neonatal Fc-receptor (FcRn) inhibition has broadened the therapeutic spectrum. Myasthenic crisis (MC), heralded by an impending myasthenic crisis (iMC), is a critical condition requiring treatments with rapid onset and sustained efficacy. Currently treatments used for iMC, including intravenous immunoglobulins and plasma exchange/immunoadsorption, have limitations, such as delayed onset of action and potential side effects.

View Article and Find Full Text PDF

In seropositive myasthenia gravis (MG), complement inhibition has been shown to be an effective and a fast-acting therapeutic option. Myasthenic crisis (MC), usually preceded by impending MC, is a life-threatening complication requiring highly effective treatments with rapid onset of action. Currently used treatment options of MC are limited, consisting mainly of symptomatic and immune therapies, that is, intravenous immunoglobulins and plasma exchange/immunoadsorption.

View Article and Find Full Text PDF

The initial six months following HIV infection have a high viral load. Nonspecific presentations might lead to the missing primary HIV diagnosis. Multiorgan and multisystem diagnosis is a rare presentation of primary HIV.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!